What the company does
GI Innovation is a South Korean biotechnology company that develops next-generation immunotherapy drugs, medicines that harness the immune system to fight cancer and allergies.
Its drug candidates target oncology and allergic disease, and its business model centers on licensing these candidates to larger pharmaceutical partners at early development stages rather than commercializing them independently. Listed on KOSDAQ, Korea's tech-focused stock exchange, the company's core structural fact is that it operates primarily as a technology-licensing business, having completed multiple global licensing deals. Its proprietary GI-SMART™ platform is used to discover and engineer novel fusion-protein drug candidates.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$3.9M
- FY2024US$17.6K
- FY2025US$4.2M
Operating profit
- FY2023−US$38.6M
- FY2024−US$35M
- FY2025−US$29.5M
Net income
- FY2023−US$40.2M
- FY2024−US$42.6M
- FY2025−US$25.5M
Key ratios (FY2025)
Why it matters · Context, not a recommendation
The company has received clinical-stage funding support from Korea's national drug-development foundation, KDDF, across several of its pipeline programs.
Filings
All disclosures · English when translatedPrice charts coming soon
Interactive price history isn't here yet. Would you use it?